Last reviewed · How we verify
QIV-HD by SC
At a glance
| Generic name | QIV-HD by SC |
|---|---|
| Also known as | High-Dose Influenza Vaccine Quadrivalent (SC) |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older (PHASE3)
- Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QIV-HD by SC CI brief — competitive landscape report
- QIV-HD by SC updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI